Northland reaffirmed its positive outlook on AMD stock (NASDAQ:AMD), maintaining an Outperform rating and a price target of $175.00. The semiconductor giant, currently valued at $188 billion, is ...

AstraZeneca has unveiled plans to invest around $570 million in Canada and add around 700 new jobs, describing the county as ...

"In our view, the ability to generate high quality wet-lab data is critical for advancement," analyst says in initiating ...

Needham analyst has initiated coverage on Absci Corporation (NASDAQ:ABSI), a drug and target discovery company that harnesses ...

The hospitality software company reported adjusted earnings of 38 cents per share, beating Wall Street’s call for 31 cents.

Absci Corp. (NASDAQ:ABSI) shares, currently trading at $3.22, received a positive outlook from Needham as the firm began coverage with a Buy rating and set a price target of $9.00. The stock has shown ...

and AMD™s $20M equity investment validates Absci™s technology and leadership in AI-drug discovery." This article was generated with the support of AI and reviewed by an editor. For more information ...

Across the recent three months, 7 analysts have shared their insights on Absci ABSI, expressing a variety of opinions spanning from bullish to bearish. In the table below, you'll find a summary of ...

AMD stock (NASDAQ:AMD) has seen a meaningful sell-off over the past week, declining by about 11% over the last five trading days. The stock also remains down by about 25% since early 2024. In ...

Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy AMD Instinct™ accelerators and ROCm™ software ...